In an interview with Applied Clinical Trials' sister publication, Pharmaceutical Executive, Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, discusses what it was like transitioning from working as a gynecologic oncologist and seeing patients to working in pharma, specifically clinical trials.
Making a big change mid-career is no small feat, which is something Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, knows from experience. In this exclusive interview with Pharmaceutical Executive®, Garner reveals what it was like transitioning from working as a gynecologic oncologist and seeing patients to working in pharma, specifically in clinical trials.
Enjoy this video and want to watch more? Check out the full Pharm Exec Podcast episode.
Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, is responsible for US clinical development, medical affairs, pharmacovigilance, project planning, and regulatory affairs at Ferring Pharmaceuticals US. Garner has nearly 30 years of experience in the medical industry. Prior to joining Ferring in 2022, she held chief medical officer roles for ObsEva, a biotechnology company focused on women’s health, and Agile Therapeutics, a women’s healthcare company. Earlier, she held leadership roles in medical affairs at Myriad Genetics Laboratories and clinical development at Abbott Laboratories and Merck Research Laboratories. Garner also holds a medical degree from Harvard Medical School and has practiced in obstetrics, gynecology, gynecologic oncology, and internal medicine at Brigham and Women’s Hospital and Massachusetts General Hospital. In addition, she holds a master’s degree in public health from Harvard’s T.H. Chan School of Public Health and a bachelor’s degree from Mount Holyoke College in Massachusetts.
The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.
Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.
Paxlovid Postexposure Prophylaxis Not Found to Significantly Lower Risk of Symptomatic SARS-CoV-2
July 19th 2024Paxlovid was the first oral drug approved by the FDA to treat Covid-19 in adults who do not require supplemental oxygen and who have an increased risk of progression to severe disease.
Altuviiio Shows Sustained Protection Against Bleeding Episodes in Children with Severe Hemophilia A
July 18th 2024Altuviiio is a first-in-class, high-sustained factor VIII replacement therapy, indicated for routine prophylaxis and on-demand treatment to control bleeding episodes in adults and children with hemophilia.